The U.S. Food and Drug Administration has approved Flibanserin, the first prescription drug to boost sexual drive in women. Developed by a small company in North Carolina called Sprout Pharmaceuticals, Addyi is marketed as a drug for women with hypoactive sex drive disorder that has been rejected twice before.
WSJ’s Mark Kelly reports on the potential side effects and covers the controversy behind the pink pill.
0:00 Flibanserin, explained
0:38 Potential side effects
0:50 Controversy behind the drug
#FDA #Drug #WSJ
Source